Lineage Cell Therapeutics Inc (NYSEAMERICAN: LCTX) Brings Onboard Kevin Cook To Serve As The Company’s Chief Financial Officer

Lineage Cell Therapeutics Inc (NYSEAMERICAN: LCTX) is quite pleased to make Kevin Cook its new Chief Financial Officer, effective June 21, 2021. It believes that the official will greatly contribute to its efforts to grow and become a top cell therapy and cell Transplant Company.

The company considered Cook’s qualifications and track record

The company chose Cook after considering the value he would bring to its business. That starts with his more than 20 years of experience working in corporate finance and investment banking. The company places its bet on a leader with diverse expertise across wide-ranging financial matters, which is expected to work in favor of the company’s progress. 

It is interesting to note that the new leader has executed capital raises, adding up to about $30 billion throughout his career. He has also been a close player in overseeing many corporate development transactions. The company discloses that most of those transactions had a lot to do with life sciences companies.

The company is optimistic about Cook’s contributions to its success

The company’s CEO Brian M. Culley opines, “We believe he will be an important addition to the Lineage team and his breadth of experience will contribute significantly to our future success as we advance our product candidates into later stage clinical trials and seek to align strategically with financial and developmental partners to support our further growth.”

Culley considers Kevin to be exceptionally talented and skilled as well. He exudes confidence in the leader’s track record and other attributes, outlining that he will significantly contribute to the company’s overall success. He closely references the various strategic and financial disciplines that the leader oversaw.

Mr. Cook is happy about his appointment and looks forward to becoming a team player to help the company achieve the highest levels of business success.